Galecto, Inc. (GLTO) NASDAQ
22.98
-1.87(-7.53%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
22.98
-1.87(-7.53%)
Currency In USD
| Previous Close | 24.85 |
| Open | 24.42 |
| Day High | 25.45 |
| Day Low | 22.9 |
| 52-Week High | 38.33 |
| 52-Week Low | 2.01 |
| Volume | 1,563 |
| Average Volume | 480,389 |
| Market Cap | 36.71M |
| PE | -1.9 |
| EPS | -12.11 |
| Moving Average 50 Days | 26.12 |
| Moving Average 200 Days | 13.34 |
| Change | -1.87 |
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with two clinical proof-of-concept da
Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mar 04, 2026 1:00 PM GMT
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2, 2026, to four newly-hired, no
Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leer